Evidence map›Paper›PMID 39240221›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2024

Hepatocellular Carcinoma Etiology Drives Survival Outcomes: A Population-Based Analysis.

Hannah M Cranford, Patricia D Jones, Robert J Wong, Qinran Liu, Erin N Kobetz, Isildinha M Reis, Tulay Koru-Sengul, Paulo S Pinheiro

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001-2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. The Role of Galectin-3 in Liver Inflammation and Fibrosis.Journal of inflammation research · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. miRNAs in HCC, pathogenesis, and targets.Hepatology (Baltimore, Md.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hannah M CranfordDivision of Epidemiology and Population Health Sciences, Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida.ORCID 0000-0002-9502-2864
Patricia D JonesDepartment of Medicine, University of Miami School of Medicine, Miami, Florida.ORCID 0000-0003-4189-6731
Robert J WongDivision of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, California.ORCID 0000-0002-8923-2806
Qinran LiuDivision of Epidemiology and Population Health Sciences, Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida.ORCID 0000-0001-7090-8485
Erin N KobetzDepartment of Medicine, University of Miami School of Medicine, Miami, Florida.ORCID 0000-0001-9215-5525
Isildinha M ReisSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida.ORCID 0000-0002-7695-8771
Tulay Koru-SengulSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida.ORCID 0000-0003-0974-8405
Paulo S PinheiroDivision of Epidemiology and Population Health Sciences, Department of Public Health Sciences, University of Miami School of Medicine, Miami, Florida.ORCID 0000-0001-8502-835X

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI George S. Grills · 2019 to 2026
$24.1M
Racial and Ethnic Disparities in Hepatocellular Carcinoma Surveillance Among Patients with Cirrhosis Across Five Safety Net OrganizationsR01MD017063 · NIMHD · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Robert John Wong · 2022 to 2026
$2.8M
National Institutes of Health (NIH) R01MD017063-03NCI NIH HHS P30 CA240139NIMHD NIH HHS R01 MD017063Sylvester Comprehensive Cancer Center, University of Miami Health Systems (Sylvester Comprehensive Cancer Center) P30CA240139
6 · The paper itself

Abstract

backgroundPrevious survival studies on hepatocellular carcinoma (HCC) by etiology are limited to hospital-based series, restricted cohorts, and monolithic etiologic categories. We studied population-based survival by seven mutually exclusive HCC etiologic groups-standalone hepatitis-C virus (HCV), hepatitis-B virus (HBV), alcohol-related liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and dual etiology HCV-HBV, HCV-ALD, and HBV-ALD-accounting for clinical and sociodemographic characteristics.

methodsAll HCC cases diagnosed during 2005 to 2018 from the Florida Cancer Registry were linked for etiology using statewide discharge and viral hepatitis data. We performed a cause-specific survival analysis including Cox regression for the matched 15,616 cases by HCC etiology.

resultsThe leading etiology was HCV only (n = 4,983; 31.9%); the leading dual etiology was HCV-ALD (n = 2,552; 16.3%). The five-year adjusted survival was low-17.6% overall and <22% across all HCC etiologies. ALD-related etiologies [ALD only (14.4%; 95% confidence interval (CI), 12.7-16.0), HCV-ALD (10.2%; 95% CI, 8.7-11.7), and HBV-ALD (8.2%; 95% CI, 2.2-14.1)] showed lower survival than non-ALD causes-HCV only, HBV only, and NAFLD only. After adjustment for clinical and sociodemographic covariates, ALD and HBV-ALD HCC had 1.20 (95% CI, 1.13-1.27) and 1.28 (95% CI, 1.06-1.54) times higher risk of death compared with those with HCV-only HCC.

conclusionsALD only and dual etiologies involving ALD show worse prognosis for HCC compared with viral etiology alone. To increase survival, improved screening and treatment are needed for patients with multiple HCC risk factors. IMPACT: Understanding US disparities in HCC survival by etiology can help guide the identification of etiologically specific biomarkers and potential therapeutic targets and inform public health measures.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAdultAgedFemaleFloridaHepatitis BHepatitis CHumansLiver Diseases, AlcoholicMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseRegistriesRisk FactorsSurvival Analysis

Identifiers

PMID39240221
PMCPMC11611647

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.